Login / Signup

Insights from compassionate use of tocilizumab for COVID-19 to inform appropriate design of randomised controlled trials.

Emma H BakerKamal PatelJonathan BallSarah EdwardsThomas S HarrisonArvind KaulMickey KohSanjeev KrishnaSusannah LeaverVinodh KumarDaniel M Forton
Published in: British journal of clinical pharmacology (2020)
Keyphrases
  • coronavirus disease
  • sars cov
  • rheumatoid arthritis
  • juvenile idiopathic arthritis
  • rheumatoid arthritis patients
  • respiratory syndrome coronavirus
  • disease activity